Type II Diabetes
Type 2 Diabetes Crisis in Adolescents
09/16/08
Type II Diabetes
Mediterranean Diet May Protect Against Type 2 Diabetes
08/18/08
Type II Diabetes
Diabetes and Depression
07/10/08
Type II Diabetes
Reducing Diabetic Mortality
07/03/08
Type II Diabetes
Type 2 Diabetes Mortality Rate in Decline
06/04/08
Type II Diabetes
Reduce Children's Risk of Type 2 Diabetes
05/28/08
Type II Diabetes
More Evidence of Heart Harm from Thiazolidinedione Diabetes Medication
12/19/07
Type II Diabetes
Another study has revealed substantial heart risks among thiazolidinedione users—especially among older adults.
Battling Third Cause of Type 2 Diabetes
09/13/07
Prediabetes and Impaired Glucose Tolerance, Type II Diabetes, Nutrition & Exercise, Living Well, Treatment Options, Prevention, General
Since the scientific identified a third cause of type 2 diabetes, we have to ask the question, how do we battle it? It may be too early for answers, but it is a great time to ask .
Diabetes is a problem that arises when one or both of the following conditions occur:
- A person's body cannot make enough insulin.
- A person's body is not able to use the insulin it produces to process blood sugar
Rosiglitazone Heart Risk Concerns Renewed
09/12/07
Diabetes Medications, Prediabetes and Impaired Glucose Tolerance, Type II Diabetes, Research, General
Pioglitazone Reduced Heart Attack, Increased Heat Failure
09/11/07
Diabetes Medications, Prediabetes and Impaired Glucose Tolerance, Type II Diabetes, Treatment Options, Prevention, General
CHICAGO – It is hard to know which medications to use to lower blood glucose levels. Beside their potency as anti-diabetes medications, diabetics must also consider side effects. Many of them are potentially serious.
A study combining previous research suggests that use of pioglitazone, marketed as brand name Actos, significantly reduces the risk of heart attack, stroke, and death, but increases the risk for serious heart failure, according to an article in the September 12 issue of JAMA. The risk of heart failure is low, while the reduction in heart attack rate is high. As a result, we suspect that many doctors will be migrating their patients to Actos (brand name for pioglitazone).